Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

MERUS LABS INTERNATIONAL INC > Q ok?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2140)
•••
Comment by lscfaon Aug 15, 2016 9:27am
134 Views
Post# 25141591

RE:Q ok?

RE:Q ok?A loss is not a loss, dumbass....eps is - $0.04 but cfps is + $0.07....also, mgmt continues to understate guidance by ignore the $8 million in manufacturing savings set to start  at year end.....
thedave2006 wrote: a loss is a loss but revs and ebidta is improving.

https://ca.finance.yahoo.com/news/merus-labs-reports-fiscal-q3-110000202.html


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities